Clinical Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hohaus, S.
Right arrow Articles by Leone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hohaus, S.
Right arrow Articles by Leone, G.
Clinical Cancer Research Vol. 11, 2175-2179, March 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma

Stefan Hohaus, Annalisa Di Ruscio, Annalaura Di Febo, Giuseppina Massini, Francesco D'Alo', Francesco Guidi, Giovanna Mansueto, Maria Teresa Voso and Giuseppe Leone

Istituto di Ematologia, Universita' Cattolica S. Cuore, Rome, Italy

Requests for reprints: Stefan Hohaus, Istituto di Ematologia, Universita' Cattolica S. Cuore L.go A. Gemelli, 1, 00168 Rome, Italy. Phone: 39-6-30154180; Fax: 39-6-35503777; E-mail: stefanhohaus{at}hotmail.com.

Purpose: Glutathione S-transferase P1 (GSTP1) is a member of the GST enzyme superfamily that is important for the detoxification of several cytotoxic drugs and their by-products. A single nucleotide polymorphism results in the substitution of isoleucine (Ile) to valine (Val) at codon 105, causing a metabolically less active variant of the enzyme. We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkin's lymphoma.

Experimental Design: The Ile105Val polymorphism in the GSTP1 gene was analyzed using a PCR-RFLP technique. Ninety-seven patients with Hodgkin's lymphoma were included and associations with patient characteristics and treatment outcome were analyzed.

Results: The GSTP1 Ile105Val polymorphism was associated in a dose-dependent fashion with an improved failure-free survival in patients with Hodgkin's lymphoma (P = 0.02). The probability of 5-year survival for patients homozygous for the 105Val/105Val GSTP1 genotype was 100%, for heterozygous patients 74% (95% confidence interval, 56-85), and for patients homozygous for the 105Ile/105Ile genotype 43% (95% confidence interval, 23-61). The Cox multivariate analysis showed that GSTP1 codon 105 genotype was an independent prognostic factor.

Conclusions: The GSTP1 genotype predicts clinical outcome in patients with Hodgkin's lymphoma.

Key Words: Hodgkin's lymphoma • GSTP1 • polymorphism • prognostic factors




This article has been cited by other articles:


Home page
BloodHome page
V. Ribrag, S. Koscielny, O. Casasnovas, C. Cazeneuve, P. Brice, F. Morschhauser, J. Gabarre, A. Stamatoullas, G. Lenoir, G. Salles, et al.
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis
Blood, April 2, 2009; 113(14): 3307 - 3313.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
N. Barahmani, S. Carpentieri, X.-N. Li, T. Wang, Y. Cao, L. Howe, L. Kilburn, M. Chintagumpala, C. Lau, and M. F. Okcu
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma
Neuro-oncol, January 1, 2009; 11(3): 292 - 300.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. A. Doussis-Anagnostopoulou, T. P. Vassilakopoulos, I. Thymara, P. Korkolopoulou, M. K. Angelopoulou, M. P. Siakantaris, S. I. Kokoris, E. M. Dimitriadou, C. Kalpadakis, M. Matzouranis, et al.
Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma
Clin. Cancer Res., March 15, 2008; 14(6): 1759 - 1766.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
D. L. White, D. Li, Z. Nurgalieva, and H. B. El-Serag
Genetic Variants of Glutathione S-Transferase as Possible Risk Factors for Hepatocellular Carcinoma: A HuGE Systematic Review and Meta-Analysis
Am. J. Epidemiol., February 15, 2008; 167(4): 377 - 389.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Voso, E Fabiani, F D'Alo', F Guidi, A Di Ruscio, S Sica, L Pagano, M Greco, S Hohaus, and G Leone
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes
Ann. Onc., September 1, 2007; 18(9): 1523 - 1528.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa
Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors
J. Clin. Oncol., February 20, 2007; 25(6): 708 - 714.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.